April 14, 2020

Personalis, Inc. Expands Genomics Portfolio Across Disease Areas With Launch of Pharma Research Solutions for Use in Early Drug Discovery and Preclinical Studies

MENLO PARK, Calif.--(BUSINESS WIRE)--Apr. 14, 2020--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of their Pharma Research Solutions, the latest expansion of the company’s portfolio of comprehensive genomics assays and analytics. These solutions, which leverage Personalis’ patented ACE Technology, are designed for use in early drug discovery and preclinical studies in oncology, but also other disease areas. These offerings complement Personalis’ comprehensive immunogenomics platform, ImmunoID NeXT™, which is currently used for clinical biomarker and companion diagnostic development in translational research and clinical trials by the company’s pharmaceutical partners.

“Our Pharma Research Solutions provide our customers with access to a broad suite of both proprietary and standard assays from targeted DNA and RNA panels through to whole genome and whole exome and transcriptome services. Our expansive sample processing and sequencing capacity, combined with our experience and expertise in executing large-scale projects as part of biopharma oncology clinical trials as well as the VA Million Veterans Program, makes us the ideal partner for pharmaceutical companies aiming to harmonize their genomics strategy across all preclinical and clinical programs,” said John West, CEO of Personalis. “Additionally, we have seen increasing interest amongst our pharma partners in leveraging ImmunoID NeXT and other solutions in areas such as inflammatory disease and other genetic disorders. This represents both the broad applicability of our technology and a potentially large growth opportunity for our business.”

The Pharma Research Solutions integrate Personalis’ ACE Technology to improve sequencing performance in complex, difficult-to-sequence regions of the genome that are insufficiently covered by conventional NGS approaches. The assays and bioinformatics capabilities offered by Personalis’ Pharma Research Solutions can enable the identification of novel drug targets and the generation of deeper insights into drug candidates’ mechanisms of action and associated resistance mechanisms in human and non-human models -- in a cost-effective and highly-scalable manner. These solutions also facilitate the company’s pursuit of new, large-scale population sequencing projects. Every step in the process from nucleic acid extraction and library preparation through to sequencing is performed in a CLIA-certified/CAP-accredited laboratory, with downstream analysis conducted using a framework of advanced algorithms.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis ImmunoID NeXT Platform™ is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding the use of Personalis’ Pharma Research Solutions, ACE Technology or NeXT platform in drug discovery, preclinical or clinical studies, clinical biomarker or companion diagnostic development, the company’s services for the VA Million Veterans Program or other large-scale population sequencing projects, the potential growth opportunities for Personalis’ business and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
415-202-5678

Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

Source: Personalis, Inc.